Article

A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial.

University of Florida College of Medicine-Jacksonville, 655 W. Eighth Street, Jacksonville, FL 32209, USA.
European Heart Journal (Impact Factor: 14.1). 01/2011; 32(7):838-46. DOI: 10.1093/eurheartj/ehq494
Source: PubMed

ABSTRACT Patients with diabetes mellitus (DM) have increased platelet reactivity and reduced platelet response to clopidogrel compared with patients without DM. Prasugrel, a more potent antiplatelet agent, is associated with greater reductions in ischaemic events compared with clopidogrel, particularly in patients with DM. The aim of this study was to perform serial pharmacodynamic assessments of prasugrel with high-dose clopidogrel in patients with DM.
Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 was a prospective, randomized, double-blind, crossover study in patients with type 2 DM and coronary artery disease (CAD). Patients (n= 35) were randomly assigned to either prasugrel 60 mg loading dose (LD)/10 mg maintenance dose (MD) or clopidogrel 600 mg LD/150 mg MD over two 1-week treatment periods separated by a 2-week washout period. Platelet function was assessed by VerifyNow® P2Y12 assay, light transmission aggregometry, and vasodilator-stimulated phosphoprotein phosphorylation at 0, 1, 4, and 24 h and 7 days. Greater platelet inhibition by VerifyNow® P2Y12 was achieved by prasugrel compared with clopidogrel at 4 h post-LD (least squares mean, 89.3 vs. 27.7%, P< 0.0001; primary endpoint). The difference in platelet inhibition between prasugrel and clopidogrel was significant from 1 h through 7 days (P < 0.0001). Similar results were obtained using all other platelet function measures. Prasugrel resulted in fewer poor responders at all time points irrespective of definition used.
In patients with type 2 DM and CAD, standard-dose prasugrel is associated with greater platelet inhibition and better response profiles during both the loading and maintenance periods when compared with double-dose clopidogrel.

0 Bookmarks
 · 
164 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the pharmacodynamic effects of switching from ticagrelor to prasugrel. Clinicians may need to switch between more potent P2Y12 inhibitors because of side effects or use of a once-daily dosing regimen due to compliance issues. After a 3-5 day run-in phase with ticagrelor 180-mg loading dose (LD) followed by ticagrelor 90-mg twice-daily maintenance dose (MD), aspirin-treated subjects (n=110) with stable coronary artery disease were randomized to continue ticagrelor or switch to prasugrel 10 mg once-daily MD, with or without a 60-mg LD. Pharmacodynamic assessments were defined by P2Y12 reaction unit (PRU, VerifyNow(®) P2Y12 assay) and platelet reactivity index (PRI, vasodilator-stimulated phosphoprotein phosphorylation assay) at baseline (before and after the run-in phase) and 2, 4, 24, and 48 hours and 7 days after randomization. Platelet reactivity was significantly greater at 24 and 48 hours after switching to prasugrel versus continued therapy with ticagrelor, although to a lesser extent in those receiving an LD. Mean PRU remained significantly higher in the combined prasugrel group versus ticagrelor (least-squares mean difference: 46; 95% confidence interval [CI]: 25-67) and did not meet the primary non-inferiority endpoint (upper limit of the CI ≤45), although PRU in the prasugrel cohort was lower at 7 days than at 24 or 48 hours. Accordingly, rates of high on-treatment platelet reactivity (HPR) were higher at 24 and 48 hours in both prasugrel groups; at 7 days there was no difference in HPR frequency between the combined prasugrel and ticagrelor groups. As compared to continued ticagrelor therapy, switching from ticagrelor to prasugrel therapy is associated with an increase in platelet reactivity that is partially mitigated by the administration of an LD.
    Journal of the American College of Cardiology 12/2013; · 14.09 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Prasugrel and ticagrelor are next-generation antiplatelet agents that provide a rapider and more potent inhibition of platelet P2Y12 receptor than clopidogrel. In combination with aspirin, these new P2Y12 inhibitors are now the first line treatments for patients with acute coronary syndrome. However, these potent antiplatelet agents introduce a new paradigm in the daily management of antithrombotic drugs, particularly when an invasive procedure is planned. The pharmacology of these antiplatelet agents, and the results of the main clinical trials, are reviewed with a special focus on good prescription practices (indications, contra-indications, drug interactions), and on peri-operative management. Strategies are proposed for safely reducing the bleeding risk in elderly patients, in patients requiring concomitant oral anticoagulant therapy, or in patients with an increased haemorrhagic risk.
    European Journal of Internal Medicine 01/2014; · 2.05 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: L’inhibition effective du récepteur plaquettaire P2Y12 est primordiale dans le traitement des patients présentant un syndrome coronaire aigu (SCA), en particulier lors de l’exécution d’une intervention coronaire percutanée (ICP) avec pose de stent. Selon les recommandations, une revascularisation précoce et un traitement antiplaquettaire intensif sont clés pour réduire les complications secondaires à l’ischémie myocardique et prévenir la récurrence d’événements cardiovasculaires. Jusqu’à un passé récent, clopidogrel a été le produit de référence pour inhiber le récepteur P2Y12, cependant, en raison d’un certain nombre de limitations de son action antiplaquettaire, de nouveaux agents, plus constants dans leur effet, plus rapides et plus puissants, ont été développés. Prasugrel et ticagrelor sont maintenant les molécules de première ligne recommandées chez les patients présentant un SCA sans sus-décalage du segment ST (NSTE-SCA) ou avec sus-décalage du segment ST (STE-SCA), en raison de l’existence de larges études randomisées ayant démontré un bénéfice clinique net de ces produits supérieur à clopidogrel, comme le mentionnent les recommandations européennes. Bien qu’aucune n’étude n’ait directement comparé les deux produits, à ce jour l’analyse des données suggère que certains profils de patients, comme les diabétiques, les patients avec un STEMI, les insuffisants rénaux ou les sujets âgés, tirent plus de bénéfice avec l’une ou l’autre des molécules. Des études supplémentaires sont nécessaires pour confirmer ces différences et répondre à des questions restées en suspens quant à l’utilisation optimale de ces produits, consistant à favoriser leur efficacité tout en réduisant leurs effets secondaires tels que les saignements. Le but de cette revue de la littérature est d’apporter une vue d’ensemble sur les molécules actuelles antagonistes du récepteur P2Y12 dans le traitement du SCA, en insistant sur les problématiques concernant le choix approprié de la molécule, le moment de son administration, le risque de saignement et le rôle futur d’un traitement personnalisé grâce aux tests de fonction plaquettaire et génétiques.
    Archives of cardiovascular diseases 01/2014; · 0.66 Impact Factor

Full-text (2 Sources)

View
38 Downloads
Available from
Jun 5, 2014